👪

Inheritance

2

Autosomal Recessive HP:0000007

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:33193648 SUPPORT Human Clinical

"Usher syndrome (USH) is an autosomal recessive (AR) disorder that permanently and severely affects the senses of hearing, vision, and balance."

Confirms the autosomal recessive inheritance pattern of Usher syndrome.

Digenic inheritance HP:0010984

In addition to the classic autosomal recessive monogenic forms, a subset of Usher syndrome shows digenic inheritance, in which a heterozygous PDZD7 variant contributes together with variants in a second Usher gene (e.g., ADGRV1/GPR98 or USH2A); PDZD7 also acts as a retinal disease modifier.

Digenic inheritance

Show evidence (1 reference)

PMID:20440071 SUPPORT Human Clinical

"Further, heterozygous PDZD7 mutations were present in patients with truncating mutations in USH2A, G protein-coupled receptor 98 (GPR98; also known as USH2C), and an unidentified locus."

A heterozygous truncating PDZD7 variant was found in Usher patients who also carried mutations in a second Usher gene, supporting a digenic contribution of PDZD7.

◆

Subtypes

3

Usher syndrome type 1 MONDO:0010168

Most severe form. Congenital profound bilateral sensorineural hearing loss, absent vestibular responses (causing delayed motor development), and prepubertal onset of retinitis pigmentosa. Caused by biallelic mutations in MYO7A (USH1B), USH1C (harmonin), CDH23 (USH1D), PCDH15 (USH1F), or USH1G (SANS/sans).

Usher syndrome type 2 MONDO:0016484

Most common form. Moderate-to-severe congenital hearing loss that is sloping (worse at high frequencies), generally normal vestibular function, and onset of retinitis pigmentosa in the first or second decade. Caused by biallelic mutations in USH2A (usherin), ADGRV1 (USH2C, GPR98/VLGR1), or WHRN (USH2D, whirlin).

Usher syndrome type 3 MONDO:0016485

Progressive postlingual sensorineural hearing loss, variable vestibular dysfunction, and variable-onset retinitis pigmentosa. Caused by biallelic mutations in CLRN1 (clarin-1). Particularly prevalent in Finnish and Ashkenazi Jewish populations.

⚙

Pathophysiology

4

Usher Interactome Disruption in the Hair Bundle

The Usher proteins (myosin VIIa, harmonin, cadherin-23, protocadherin-15, sans, usherin, ADGRV1/VLGR1, whirlin, clarin-1) form an interconnected network that builds and maintains the cohesion of the stereocilia hair bundle in cochlear and vestibular hair cells. Cadherin-23 and protocadherin-15 constitute the tip-link that gates the mechanotransduction channel, while harmonin, sans, and myosin VIIa anchor the link complex and stabilize bundle architecture during development. Loss of function of any Usher gene disrupts hair-bundle cohesion and tip-link integrity.

cochlear inner hair cell CL:0000589 cochlear outer hair cell CL:0000601

mechanoreceptor differentiation GO:0042490 ⚠ ABNORMAL

spiral organ of Corti UBERON:0002227

Downstream

Hair Cell Mechanotransduction Failure Disorganized hair bundles and disrupted tip-links abolish the mechanotransduction current.

Photoreceptor Connecting Cilium Dysfunction The same Usher interactome is also required at the photoreceptor periciliary/connecting-cilium region, so loss of any Usher protein concurrently disrupts photoreceptor ciliary transport.

Show evidence (2 references)

PMID:24239741 SUPPORT Model Organism

"In mature hair cells, homodimers of the Usher cadherins, cadherin 23 and protocadherin 15, interact to form a structural fiber, the tip link, and the linkages that anchor the taller stereocilia's actin cytoskeleton core to the shorter adjacent stereocilia and the elusive mechanotransduction..."

Establishes that cadherin-23/protocadherin-15 form the tip-link and that disruption explains the deafness phenotype.

PMID:16987892 SUPPORT Model Organism

"The localization of the Usher proteins and the phenotype in animal models indicate that the Usher protein complex is essential in the morphogenesis of the stereocilia bundle in hair cells and in the calycal processes of photoreceptor cells."

Supports the role of the Usher protein complex in stereocilia bundle morphogenesis.

Hair Cell Mechanotransduction Failure

Disruption of the tip-link and hair-bundle architecture prevents deflection-gated opening of the mechanotransduction channel, so hair cells cannot convert sound-evoked or head-movement-evoked bundle deflection into a receptor potential. The result is sensorineural hearing loss and, in USH1, vestibular areflexia. The severity and onset (congenital vs progressive) depend on whether the protein is required for bundle development or maintenance.

cochlea auditory hair cell CL:4023120

sensory perception of sound GO:0007605 ↓ DECREASED

Downstream

Sensorineural Hearing Loss Loss of cochlear hair cell transduction causes sensorineural hearing loss.

Congenital Sensorineural Hearing Loss When the Usher protein is required for hair-bundle development, transduction failure is present from birth, producing congenital sensorineural hearing loss (USH1/USH2).

Vestibular Dysfunction Loss of vestibular hair cell transduction causes vestibular areflexia, most pronounced in USH1.

Delayed Motor Development Congenital vestibular areflexia delays the acquisition of independent walking in USH1 infants.

Show evidence (1 reference)

PMID:33193648 SUPPORT In Vitro

"Disease-causing mutations in USH genes can destabilize the tip links that bind the stereocilia to each other, and cause defects in protein trafficking and stereocilia bundle morphology, thereby inhibiting mechanosensory transduction."

Directly links Usher gene mutations to inhibited mechanosensory transduction via tip-link destabilization.

Photoreceptor Connecting Cilium Dysfunction

Usher proteins are also expressed at the photoreceptor periciliary and connecting-cilium region, where they participate in protein trafficking between the inner and outer segments. Disruption of the Usher interactome here impairs periciliary structure and intersegmental transport, leading to photoreceptor stress and progressive degeneration that begins with rods (night blindness, peripheral field loss) and later involves cones.

retinal rod cell CL:0000604 photoreceptor cell CL:0000210

protein localization to cilium GO:0061512 ⚠ ABNORMAL

retina UBERON:0000966

Downstream

Photoreceptor Degeneration Impaired ciliary transport and outer-segment maintenance cause progressive photoreceptor loss.

Show evidence (1 reference)

PMID:24239741 SUPPORT Model Organism

"Recent evidence linking photoreceptor cell dysfunction in the shaker 1 mouse model for Usher syndrome to light-induced protein translocation defects, combined with localization of an Usher protein interactome at the periciliary region of the photoreceptors suggests Usher proteins might regulate..."

Supports an Usher-interactome role in periciliary protein trafficking between photoreceptor inner and outer segments.

Photoreceptor Degeneration

Progressive rod-then-cone photoreceptor degeneration produces the clinical picture of retinitis pigmentosa: nyctalopia and peripheral visual field constriction first, followed by central acuity loss. Fundus examination shows bone-spicule pigmentation and the electroretinogram becomes reduced or extinguished.

photoreceptor cell CL:0000210

visual perception GO:0007601 ↓ DECREASED

Downstream

Retinitis Pigmentosa Progressive photoreceptor loss manifests clinically as retinitis pigmentosa.

Night Blindness Early rod loss produces nyctalopia.

Constricted Visual Fields Progressive peripheral photoreceptor loss constricts the visual field.

Abnormal Electroretinogram Photoreceptor dysfunction reduces or extinguishes the ERG response.

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"RP, a progressive bilateral symmetric degeneration of photoreceptors in the retina, develops in early adolescence, resulting in progressively constricted visual fields first, due to rod photoreceptor cell loss, followed by impaired visual acuity due to cone photoreceptor cell loss."

Establishes the rod-then-cone progression of photoreceptor degeneration producing field loss then acuity loss.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

9

Ear 1

Sensorineural Hearing Loss Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:32995707 SUPPORT Human Clinical

"Usher syndrome has three subtypes, each being clinically and genetically heterogeneous characterised by sensorineural hearing loss and retinitis pigmentosa (RP), with or without vestibular dysfunction."

Establishes sensorineural hearing loss as a defining feature of all Usher subtypes.

Eye 5

Retinitis Pigmentosa Rod-cone dystrophy HP:0000510

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:32995707 SUPPORT Human Clinical

"Usher syndrome has three subtypes, each being clinically and genetically heterogeneous characterised by sensorineural hearing loss and retinitis pigmentosa (RP), with or without vestibular dysfunction."

Establishes retinitis pigmentosa as a defining feature of Usher syndrome.

Cataract Cataract HP:0000518

Show evidence (1 reference)

PMID:20301515 SUPPORT Human Clinical

"detect potentially treatable complications such as cataracts, refractive errors, and cystoid macular edema."

GeneReviews lists cataract among the treatable ophthalmologic complications detected on surveillance in Usher syndrome type II.

Night Blindness Nyctalopia HP:0000662

Show evidence (1 reference)

PMID:20301515 SUPPORT Human Clinical

"Retinitis pigmentosa (RP); progressive, bilateral, symmetric retinal degeneration that begins with night blindness and constricted visual fields (tunnel vision) and eventually includes decreased central visual acuity"

Documents night blindness as an early feature of the retinal degeneration in Usher syndrome.

Constricted Visual Fields Constriction of peripheral visual field HP:0001133

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:20301515 SUPPORT Human Clinical

"progressive, bilateral, symmetric retinal degeneration that begins with night blindness and constricted visual fields (tunnel vision)"

Documents progressive constriction of the visual field (tunnel vision) in Usher syndrome.

Abnormal Electroretinogram Abnormal electroretinogram HP:0000512

Show evidence (1 reference)

PMID:20301515 PARTIAL Human Clinical

"The diagnosis of USH2 is established in a proband using electrophysiologic and subjective tests of hearing and retinal function."

Indirect support: electrophysiologic (electroretinographic) testing of retinal function is part of the diagnostic evaluation, but this abstract does not state the ERG is reduced/extinguished directly, so the abnormal-ERG phenotype link is marked PARTIAL.

Other 3

Congenital Sensorineural Hearing Loss Congenital sensorineural hearing impairment HP:0008527

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Usher syndrome type I (USH1) is characterized by congenital bilateral profound sensorineural hearing loss, vestibular areflexia, and adolescent-onset retinitis pigmentosa (RP)."

Confirms congenital bilateral profound sensorineural hearing loss in USH1.

Vestibular Dysfunction Vestibular areflexia HP:0008568

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Usher syndrome type I (USH1) is characterized by congenital bilateral profound sensorineural hearing loss, vestibular areflexia, and adolescent-onset retinitis pigmentosa (RP)."

Confirms vestibular areflexia as a defining feature of USH1.

Delayed Motor Development Delayed ability to walk HP:0031936

Show evidence (1 reference)

PMID:33193648 SUPPORT Human Clinical

"Usher syndrome (USH) is an autosomal recessive (AR) disorder that permanently and severely affects the senses of hearing, vision, and balance."

Supports the balance (vestibular) component of USH that, in USH1, manifests as delayed motor development; the specific delayed-walking timing is detailed in the USH1 GeneReviews chapter.

🧬

Genetic Associations

9

MYO7A Mutations (Causative)

Gene: MYO7A hgnc:7606

Show evidence (1 reference)

PMID:32995707 SUPPORT Human Clinical

"To date, 10 causative genes have been identified for Usher syndrome, with MYO7A accounting for >50% of type 1 and USH2A contributing to approximately 80% of type 2 Usher syndrome."

Documents MYO7A as the major USH1 gene, accounting for more than 50% of type 1.

USH1C Mutations (Causative)

Gene: USH1C hgnc:12597

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."

Confirms USH1C as one of the five established USH1 genes.

CDH23 Mutations (Causative)

Gene: CDH23 hgnc:13733

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."

Confirms CDH23 as one of the five established USH1 genes.

PCDH15 Mutations (Causative)

Gene: PCDH15 hgnc:14674

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."

Confirms PCDH15 as one of the five established USH1 genes.

USH1G Mutations (Causative)

Gene: USH1G hgnc:16356

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."

Confirms USH1G as one of the five established USH1 genes.

USH2A Mutations (Causative)

Gene: USH2A hgnc:12601

Show evidence (1 reference)

PMID:32995707 SUPPORT Human Clinical

"To date, 10 causative genes have been identified for Usher syndrome, with MYO7A accounting for >50% of type 1 and USH2A contributing to approximately 80% of type 2 Usher syndrome."

Documents USH2A as the predominant USH2 gene, accounting for approximately 80% of type 2.

ADGRV1 Mutations (Causative)

Gene: ADGRV1 hgnc:17416

Show evidence (1 reference)

PMID:20301515 SUPPORT Human Clinical

"Identification of biallelic pathogenic variants in one of three genes – ADGRV1, USH2A, or WHRN – establishes the diagnosis if clinical features are inconclusive."

Confirms ADGRV1 as one of the three established USH2 genes.

WHRN Mutations (Causative)

Gene: WHRN hgnc:16361

Show evidence (1 reference)

PMID:20301515 SUPPORT Human Clinical

"Identification of biallelic pathogenic variants in one of three genes – ADGRV1, USH2A, or WHRN – establishes the diagnosis if clinical features are inconclusive."

Confirms WHRN as one of the three established USH2 genes.

CLRN1 Mutations (Causative)

Gene: CLRN1 hgnc:12605

Show evidence (2 references)

PMID:11524702 SUPPORT Human Clinical

"USH3, the candidate gene that we identified, encodes a 120-amino-acid protein."

Identifies the USH3 causative gene (subsequently named CLRN1/clarin-1) whose mutations underlie Usher syndrome type 3.

PMID:11524702 SUPPORT Human Clinical

"Usher syndrome type 3 (USH3) is an autosomal recessive disorder characterized by progressive hearing loss, severe retinal degeneration, and variably present vestibular dysfunction, assigned to 3q21-q25."

Defines USH3 (the CLRN1/clarin-1 disorder at 3q21-q25) as autosomal-recessive hearing loss with retinal degeneration and variable vestibular dysfunction.

💊

Medical Actions

5

Vestibular Physical Therapy

Action: physical therapy MAXO:0000011

Physical therapy / vestibular rehabilitation is recommended to manage the vestibular dysfunction and imbalance of USH1 (and to a lesser degree USH3) throughout the disease course, beginning in childhood.

Target Phenotypes: Abnormal vestibular function HP:0001751

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Physical therapy is recommended to manage vestibular dysfunction and imbalance throughout the disease course"

GeneReviews recommends physical therapy for the vestibular dysfunction and imbalance of USH1.

Cochlear Implantation

Action: cochlear device implantation MAXO:0009025

Cochlear implantation provides auditory rehabilitation for the severe-to-profound sensorineural hearing loss of USH1 and is most effective when performed early in childhood, typically before age one year.

Target Phenotypes: Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:20301442 SUPPORT Human Clinical

"Cochlear implantation should be considered as young as medically feasible, typically before age one year."

GeneReviews recommends early cochlear implantation for the profound hearing loss of USH1.

Hearing Aids

Action: hearing aid usage MAXO:0009030

Conventional amplification with hearing aids is used for the moderate-to- severe hearing loss of USH2 and early USH3.

Target Phenotypes: Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:20301515 SUPPORT Human Clinical

"Treatment of manifestations: Early fitting of hearing aids and speech training."

GeneReviews recommends early hearing-aid fitting for the hearing loss of USH2.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Genetic counseling addresses the autosomal recessive recurrence risk and informs reproductive decision-making and cascade testing.

Show evidence (1 reference)

PMID:20301515 SUPPORT Human Clinical

"USH2 is inherited in an autosomal recessive manner. Each subsequent pregnancy of a couple who have had a child with Usher syndrome type II has a 25% chance of resulting in an affected child"

Supports genetic counseling for the autosomal recessive recurrence risk of Usher syndrome.

Gene Therapy

Action: Gene Therapy NCIT:C15238

Investigational gene-replacement, gene-editing, and antisense-oligonucleotide approaches target the retinal degeneration, including dual-AAV delivery for the large MYO7A and USH2A genes. No therapy is approved.

Show evidence (1 reference)

PMID:32995707 SUPPORT Human Clinical

"While there is currently no available approved treatment for the RP, various therapeutic strategies are in development or in clinical trials for Usher syndrome, including gene replacement, gene editing, antisense oligonucleotides and small molecule drugs."

Documents the investigational gene-replacement/editing/ASO strategies targeting the retinal degeneration, none yet approved.

{ }

Source YAML

click to show

name: Usher Syndrome
creation_date: "2026-06-22T00:00:00Z"
category: Mendelian
synonyms:
- Usher syndrome
- Retinitis pigmentosa-deafness syndrome
- Hallgren syndrome
- Deaf-blindness, Usher type
description: >
  Usher syndrome is the most common inherited cause of combined deaf-blindness,
  an autosomal recessive disorder characterized by sensorineural hearing loss,
  progressive retinitis pigmentosa, and, in some forms, vestibular dysfunction.
  The disease results from mutations in genes encoding components of the Usher
  protein interactome, a network of proteins that organize the cohesion of the
  stereocilia hair bundle in cochlear and vestibular hair cells and that
  participate in trafficking at the photoreceptor periciliary/connecting-cilium
  region. Three classical clinical types are recognized: USH1 (severe-to-profound
  congenital deafness, absent vestibular function, prepubertal-onset retinitis
  pigmentosa), USH2 (moderate-to-severe congenital hearing loss, generally normal
  vestibular function, later-onset retinitis pigmentosa), and USH3 (progressive
  postlingual hearing loss, variable vestibular involvement, variable retinitis
  pigmentosa onset).
disease_term:
  preferred_term: Usher syndrome
  term:
    id: MONDO:0019501
    label: Usher syndrome
parents:
- Inherited retinal dystrophy
- Sensorineural hearing loss
- Ciliopathy
references:
- reference: PMID:20301442
  title: "Usher Syndrome Type I."
  tags:
  - GeneReviews
- reference: PMID:20301515
  title: "Usher Syndrome Type II."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:33193648
    reference_title: "Usher Syndrome: Genetics and Molecular Links of Hearing Loss and Directions for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usher syndrome (USH) is an autosomal recessive (AR) disorder that permanently and severely affects the senses of hearing, vision, and balance."
    explanation: Confirms the autosomal recessive inheritance pattern of Usher syndrome.
- name: Digenic inheritance
  inheritance_term:
    preferred_term: Digenic inheritance
    term:
      id: HP:0010984
      label: Digenic inheritance
  description: >-
    In addition to the classic autosomal recessive monogenic forms, a subset of
    Usher syndrome shows digenic inheritance, in which a heterozygous PDZD7
    variant contributes together with variants in a second Usher gene (e.g.,
    ADGRV1/GPR98 or USH2A); PDZD7 also acts as a retinal disease modifier.
  evidence:
  - reference: PMID:20440071
    reference_title: "PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Further, heterozygous PDZD7 mutations were present in patients with
      truncating mutations in USH2A, G protein-coupled receptor 98 (GPR98; also
      known as USH2C), and an unidentified locus.
    explanation: >-
      A heterozygous truncating PDZD7 variant was found in Usher patients who
      also carried mutations in a second Usher gene, supporting a digenic
      contribution of PDZD7.
prevalence:
- population: General population (worldwide)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 4.0
  rate_high: 17.0
  percentage: 4-17 per 100,000
  notes: >-
    Usher syndrome is the most common cause of deaf-blindness worldwide.
  evidence:
  - reference: PMID:32995707
    reference_title: "Usher syndrome: clinical features, molecular genetics and advancing therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is the most common cause of deaf-blindness worldwide with a prevalence of between 4 and 17 in 100 000."
    explanation: Documents the worldwide prevalence and deaf-blindness burden of Usher syndrome.
has_subtypes:
- name: USH1
  display_name: Usher syndrome type 1
  subtype_term:
    preferred_term: Usher syndrome type 1
    term:
      id: MONDO:0010168
      label: Usher syndrome type 1
  description: >
    Most severe form. Congenital profound bilateral sensorineural hearing loss,
    absent vestibular responses (causing delayed motor development), and
    prepubertal onset of retinitis pigmentosa. Caused by biallelic mutations in
    MYO7A (USH1B), USH1C (harmonin), CDH23 (USH1D), PCDH15 (USH1F), or USH1G
    (SANS/sans).
- name: USH2
  display_name: Usher syndrome type 2
  subtype_term:
    preferred_term: Usher syndrome type 2
    term:
      id: MONDO:0016484
      label: Usher syndrome type 2
  description: >
    Most common form. Moderate-to-severe congenital hearing loss that is sloping
    (worse at high frequencies), generally normal vestibular function, and onset
    of retinitis pigmentosa in the first or second decade. Caused by biallelic
    mutations in USH2A (usherin), ADGRV1 (USH2C, GPR98/VLGR1), or WHRN (USH2D,
    whirlin).
- name: USH3
  display_name: Usher syndrome type 3
  subtype_term:
    preferred_term: Usher syndrome type 3
    term:
      id: MONDO:0016485
      label: Usher syndrome type 3
  description: >
    Progressive postlingual sensorineural hearing loss, variable vestibular
    dysfunction, and variable-onset retinitis pigmentosa. Caused by biallelic
    mutations in CLRN1 (clarin-1). Particularly prevalent in Finnish and
    Ashkenazi Jewish populations.
pathophysiology:
- name: Usher Interactome Disruption in the Hair Bundle
  description: >
    The Usher proteins (myosin VIIa, harmonin, cadherin-23, protocadherin-15,
    sans, usherin, ADGRV1/VLGR1, whirlin, clarin-1) form an interconnected
    network that builds and maintains the cohesion of the stereocilia hair bundle
    in cochlear and vestibular hair cells. Cadherin-23 and protocadherin-15
    constitute the tip-link that gates the mechanotransduction channel, while
    harmonin, sans, and myosin VIIa anchor the link complex and stabilize bundle
    architecture during development. Loss of function of any Usher gene disrupts
    hair-bundle cohesion and tip-link integrity.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  locations:
  - preferred_term: spiral organ of Corti
    term:
      id: UBERON:0002227
      label: spiral organ of cochlea
  biological_processes:
  - preferred_term: mechanoreceptor differentiation
    term:
      id: GO:0042490
      label: mechanoreceptor differentiation
    modifier: ABNORMAL
  downstream:
  - target: Hair Cell Mechanotransduction Failure
    description: >
      Disorganized hair bundles and disrupted tip-links abolish the
      mechanotransduction current.
    causal_link_type: DIRECT
  - target: Photoreceptor Connecting Cilium Dysfunction
    description: >
      The same Usher interactome is also required at the photoreceptor
      periciliary/connecting-cilium region, so loss of any Usher protein
      concurrently disrupts photoreceptor ciliary transport.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - shared Usher interactome required in both hair cells and photoreceptors
    - loss of Usher complex at the photoreceptor periciliary region
  evidence:
  - reference: PMID:24239741
    reference_title: "Usher protein functions in hair cells and photoreceptors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In mature hair cells, homodimers of the Usher cadherins, cadherin 23 and protocadherin 15, interact to form a structural fiber, the tip link, and the linkages that anchor the taller stereocilia's actin cytoskeleton core to the shorter adjacent stereocilia and the elusive mechanotransduction channels, explaining the deafness phenotype when these molecular interactions are perturbed."
    explanation: Establishes that cadherin-23/protocadherin-15 form the tip-link and that disruption explains the deafness phenotype.
  - reference: PMID:16987892
    reference_title: "Usher syndrome: molecular links of pathogenesis, proteins and pathways."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The localization of the Usher proteins and the phenotype in animal models indicate that the Usher protein complex is essential in the morphogenesis of the stereocilia bundle in hair cells and in the calycal processes of photoreceptor cells."
    explanation: Supports the role of the Usher protein complex in stereocilia bundle morphogenesis.
- name: Hair Cell Mechanotransduction Failure
  description: >
    Disruption of the tip-link and hair-bundle architecture prevents
    deflection-gated opening of the mechanotransduction channel, so hair cells
    cannot convert sound-evoked or head-movement-evoked bundle deflection into a
    receptor potential. The result is sensorineural hearing loss and, in USH1,
    vestibular areflexia. The severity and onset (congenital vs progressive)
    depend on whether the protein is required for bundle development or
    maintenance.
  cell_types:
  - preferred_term: cochlea auditory hair cell
    term:
      id: CL:4023120
      label: cochlea auditory hair cell
  biological_processes:
  - preferred_term: sensory perception of sound
    term:
      id: GO:0007605
      label: sensory perception of sound
    modifier: DECREASED
  downstream:
  - target: Sensorineural Hearing Loss
    description: Loss of cochlear hair cell transduction causes sensorineural hearing loss.
    causal_link_type: DIRECT
  - target: Congenital Sensorineural Hearing Loss
    description: >
      When the Usher protein is required for hair-bundle development, transduction
      failure is present from birth, producing congenital sensorineural hearing
      loss (USH1/USH2).
    causal_link_type: DIRECT
  - target: Vestibular Dysfunction
    description: >
      Loss of vestibular hair cell transduction causes vestibular areflexia,
      most pronounced in USH1.
    causal_link_type: DIRECT
  - target: Delayed Motor Development
    description: >
      Congenital vestibular areflexia delays the acquisition of independent
      walking in USH1 infants.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - absent vestibular input
    - impaired postural/balance control in infancy
  evidence:
  - reference: PMID:33193648
    reference_title: "Usher Syndrome: Genetics and Molecular Links of Hearing Loss and Directions for Therapy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Disease-causing mutations in USH genes can destabilize the tip links that bind the stereocilia to each other, and cause defects in protein trafficking and stereocilia bundle morphology, thereby inhibiting mechanosensory transduction."
    explanation: Directly links Usher gene mutations to inhibited mechanosensory transduction via tip-link destabilization.
- name: Photoreceptor Connecting Cilium Dysfunction
  description: >
    Usher proteins are also expressed at the photoreceptor periciliary and
    connecting-cilium region, where they participate in protein trafficking
    between the inner and outer segments. Disruption of the Usher interactome
    here impairs periciliary structure and intersegmental transport, leading to
    photoreceptor stress and progressive degeneration that begins with rods
    (night blindness, peripheral field loss) and later involves cones.
  cell_types:
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  biological_processes:
  - preferred_term: protein localization to cilium
    term:
      id: GO:0061512
      label: protein localization to cilium
    modifier: ABNORMAL
  downstream:
  - target: Photoreceptor Degeneration
    description: >
      Impaired ciliary transport and outer-segment maintenance cause progressive
      photoreceptor loss.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired intraciliary protein transport
    - outer-segment homeostatic failure
  evidence:
  - reference: PMID:24239741
    reference_title: "Usher protein functions in hair cells and photoreceptors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Recent evidence linking photoreceptor cell dysfunction in the shaker 1 mouse model for Usher syndrome to light-induced protein translocation defects, combined with localization of an Usher protein interactome at the periciliary region of the photoreceptors suggests Usher proteins might regulate protein trafficking between the inner and outer segments of photoreceptors."
    explanation: Supports an Usher-interactome role in periciliary protein trafficking between photoreceptor inner and outer segments.
- name: Photoreceptor Degeneration
  description: >
    Progressive rod-then-cone photoreceptor degeneration produces the clinical
    picture of retinitis pigmentosa: nyctalopia and peripheral visual field
    constriction first, followed by central acuity loss. Fundus examination shows
    bone-spicule pigmentation and the electroretinogram becomes reduced or
    extinguished.
  cell_types:
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  biological_processes:
  - preferred_term: visual perception
    term:
      id: GO:0007601
      label: visual perception
    modifier: DECREASED
  downstream:
  - target: Retinitis Pigmentosa
    description: Progressive photoreceptor loss manifests clinically as retinitis pigmentosa.
    causal_link_type: DIRECT
  - target: Night Blindness
    description: Early rod loss produces nyctalopia.
    causal_link_type: DIRECT
  - target: Constricted Visual Fields
    description: Progressive peripheral photoreceptor loss constricts the visual field.
    causal_link_type: DIRECT
  - target: Abnormal Electroretinogram
    description: Photoreceptor dysfunction reduces or extinguishes the ERG response.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RP, a progressive bilateral symmetric degeneration of photoreceptors in the retina, develops in early adolescence, resulting in progressively constricted visual fields first, due to rod photoreceptor cell loss, followed by impaired visual acuity due to cone photoreceptor cell loss."
    explanation: Establishes the rod-then-cone progression of photoreceptor degeneration producing field loss then acuity loss.
phenotypes:
- category: Auditory
  name: Sensorineural Hearing Loss
  description: >
    Bilateral sensorineural hearing loss, congenital and severe-to-profound in
    USH1, congenital and moderate-to-severe (sloping, high-frequency-predominant)
    in USH2, and progressive/postlingual in USH3.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:32995707
    reference_title: "Usher syndrome: clinical features, molecular genetics and advancing therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usher syndrome has three subtypes, each being clinically and genetically heterogeneous characterised by sensorineural hearing loss and retinitis pigmentosa (RP), with or without vestibular dysfunction."
    explanation: Establishes sensorineural hearing loss as a defining feature of all Usher subtypes.
- category: Auditory
  name: Congenital Sensorineural Hearing Loss
  description: >
    Congenital onset of sensorineural hearing loss is characteristic of USH1 and
    USH2.
  subtype: USH1
  phenotype_term:
    preferred_term: Congenital sensorineural hearing impairment
    term:
      id: HP:0008527
      label: Congenital sensorineural hearing impairment
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usher syndrome type I (USH1) is characterized by congenital bilateral profound sensorineural hearing loss, vestibular areflexia, and adolescent-onset retinitis pigmentosa (RP)."
    explanation: Confirms congenital bilateral profound sensorineural hearing loss in USH1.
- category: Ophthalmologic
  name: Retinitis Pigmentosa
  description: >
    Progressive rod-cone dystrophy with bone-spicule pigmentary deposits, the
    ophthalmologic hallmark of Usher syndrome. Onset is prepubertal in USH1 and
    later (first-to-second decade) in USH2.
  phenotype_term:
    preferred_term: Rod-cone dystrophy
    term:
      id: HP:0000510
      label: Rod-cone dystrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:32995707
    reference_title: "Usher syndrome: clinical features, molecular genetics and advancing therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usher syndrome has three subtypes, each being clinically and genetically heterogeneous characterised by sensorineural hearing loss and retinitis pigmentosa (RP), with or without vestibular dysfunction."
    explanation: Establishes retinitis pigmentosa as a defining feature of Usher syndrome.
- category: Ophthalmologic
  name: Cataract
  description: >
    Posterior subcapsular cataract is a common treatable ophthalmologic
    complication, especially in USH2, and is monitored during routine
    ophthalmologic surveillance.
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "detect potentially treatable complications such as cataracts, refractive errors, \nand cystoid macular edema."
    explanation: >-
      GeneReviews lists cataract among the treatable ophthalmologic complications
      detected on surveillance in Usher syndrome type II.
- category: Ophthalmologic
  name: Night Blindness
  description: >
    Nyctalopia (impaired vision in dim light) is an early symptom of the
    rod-predominant photoreceptor degeneration.
  phenotype_term:
    preferred_term: Nyctalopia
    term:
      id: HP:0000662
      label: Nyctalopia
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Retinitis pigmentosa (RP); progressive, bilateral, symmetric retinal degeneration that begins with night blindness and constricted visual fields (tunnel vision) and eventually includes decreased central visual acuity"
    explanation: Documents night blindness as an early feature of the retinal degeneration in Usher syndrome.
- category: Ophthalmologic
  name: Constricted Visual Fields
  description: >
    Progressive constriction of the peripheral visual field ("tunnel vision")
    results from peripheral photoreceptor loss.
  phenotype_term:
    preferred_term: Constriction of peripheral visual field
    term:
      id: HP:0001133
      label: Constriction of peripheral visual field
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive, bilateral, symmetric retinal degeneration that begins with night blindness and constricted visual fields (tunnel vision)"
    explanation: Documents progressive constriction of the visual field (tunnel vision) in Usher syndrome.
- category: Ophthalmologic
  name: Abnormal Electroretinogram
  description: >
    The electroretinogram is reduced or extinguished, reflecting widespread
    photoreceptor dysfunction, and is an early diagnostic finding even before
    symptomatic visual loss.
  phenotype_term:
    preferred_term: Abnormal electroretinogram
    term:
      id: HP:0000512
      label: Abnormal electroretinogram
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of USH2 is established in a proband using electrophysiologic and subjective tests of hearing and retinal function."
    explanation: >-
      Indirect support: electrophysiologic (electroretinographic) testing of
      retinal function is part of the diagnostic evaluation, but this abstract
      does not state the ERG is reduced/extinguished directly, so the abnormal-ERG
      phenotype link is marked PARTIAL.
- category: Vestibular
  name: Vestibular Dysfunction
  description: >
    Absent vestibular responses (vestibular areflexia) are characteristic of
    USH1 and cause delayed independent walking in infancy. Vestibular function
    is typically normal in USH2 and variable in USH3.
  subtype: USH1
  phenotype_term:
    preferred_term: Vestibular areflexia
    term:
      id: HP:0008568
      label: Vestibular areflexia
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usher syndrome type I (USH1) is characterized by congenital bilateral profound sensorineural hearing loss, vestibular areflexia, and adolescent-onset retinitis pigmentosa (RP)."
    explanation: Confirms vestibular areflexia as a defining feature of USH1.
- category: Neurologic
  name: Delayed Motor Development
  description: >
    Children with USH1 have delayed independent walking secondary to congenital
    vestibular areflexia.
  subtype: USH1
  phenotype_term:
    preferred_term: Delayed ability to walk
    term:
      id: HP:0031936
      label: Delayed ability to walk
  evidence:
  - reference: PMID:33193648
    reference_title: "Usher Syndrome: Genetics and Molecular Links of Hearing Loss and Directions for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usher syndrome (USH) is an autosomal recessive (AR) disorder that permanently and severely affects the senses of hearing, vision, and balance."
    explanation: >-
      Supports the balance (vestibular) component of USH that, in USH1, manifests
      as delayed motor development; the specific delayed-walking timing is
      detailed in the USH1 GeneReviews chapter.
genetic:
- name: MYO7A Mutations
  association: Causative
  subtype: USH1
  gene_term:
    preferred_term: MYO7A
    term:
      id: hgnc:7606
      label: MYO7A
  features: >
    Biallelic mutations in MYO7A (myosin VIIa) cause Usher syndrome type 1B, the
    most common USH1 subtype, accounting for more than 50% of USH1. Myosin VIIa
    is an actin-based motor protein essential for hair-bundle structure and for
    photoreceptor periciliary transport.
  evidence:
  - reference: PMID:32995707
    reference_title: "Usher syndrome: clinical features, molecular genetics and advancing therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, 10 causative genes have been identified for Usher syndrome, with MYO7A accounting for >50% of type 1 and USH2A contributing to approximately 80% of type 2 Usher syndrome."
    explanation: Documents MYO7A as the major USH1 gene, accounting for more than 50% of type 1.
- name: USH1C Mutations
  association: Causative
  subtype: USH1
  gene_term:
    preferred_term: USH1C
    term:
      id: hgnc:12597
      label: USH1C
  features: >
    Biallelic mutations in USH1C (harmonin) cause Usher syndrome type 1C.
    Harmonin is a PDZ-domain scaffold protein that organizes the Usher
    interactome at the hair-bundle upper tip-link density.
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."
    explanation: Confirms USH1C as one of the five established USH1 genes.
- name: CDH23 Mutations
  association: Causative
  subtype: USH1
  gene_term:
    preferred_term: CDH23
    term:
      id: hgnc:13733
      label: CDH23
  features: >
    Biallelic mutations in CDH23 (cadherin-23) cause Usher syndrome type 1D.
    Cadherin-23 forms the upper portion of the tip-link that gates the
    mechanotransduction channel.
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."
    explanation: Confirms CDH23 as one of the five established USH1 genes.
- name: PCDH15 Mutations
  association: Causative
  subtype: USH1
  gene_term:
    preferred_term: PCDH15
    term:
      id: hgnc:14674
      label: PCDH15
  features: >
    Biallelic mutations in PCDH15 (protocadherin-15) cause Usher syndrome type
    1F. Protocadherin-15 forms the lower part of the tip-link and pairs with
    cadherin-23.
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."
    explanation: Confirms PCDH15 as one of the five established USH1 genes.
- name: USH1G Mutations
  association: Causative
  subtype: USH1
  gene_term:
    preferred_term: USH1G
    term:
      id: hgnc:16356
      label: USH1G
  features: >
    Biallelic mutations in USH1G (SANS) cause Usher syndrome type 1G. SANS is a
    scaffold/adaptor protein that links the Usher interactome to the microtubule
    transport machinery.
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Identification of biallelic pathogenic variants in one of five genes – MYO7A, USH1C, CDH23, PCDH15, and USH1G – confirms the diagnosis."
    explanation: Confirms USH1G as one of the five established USH1 genes.
- name: USH2A Mutations
  association: Causative
  subtype: USH2
  gene_term:
    preferred_term: USH2A
    term:
      id: hgnc:12601
      label: USH2A
  features: >
    Biallelic mutations in USH2A (usherin) are the most common cause of Usher
    syndrome overall, accounting for approximately 80% of USH2. Usherin is a
    large transmembrane protein at the photoreceptor periciliary membrane and the
    base of the hair bundle.
  evidence:
  - reference: PMID:32995707
    reference_title: "Usher syndrome: clinical features, molecular genetics and advancing therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, 10 causative genes have been identified for Usher syndrome, with MYO7A accounting for >50% of type 1 and USH2A contributing to approximately 80% of type 2 Usher syndrome."
    explanation: Documents USH2A as the predominant USH2 gene, accounting for approximately 80% of type 2.
- name: ADGRV1 Mutations
  association: Causative
  subtype: USH2
  gene_term:
    preferred_term: ADGRV1
    term:
      id: hgnc:17416
      label: ADGRV1
  features: >
    Biallelic mutations in ADGRV1 (VLGR1/GPR98) cause Usher syndrome type 2C.
    ADGRV1 is a very large adhesion G-protein-coupled receptor of the ankle-link
    complex.
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Identification of biallelic pathogenic variants in one of three genes – ADGRV1, USH2A, or WHRN – establishes the diagnosis if clinical features are inconclusive."
    explanation: Confirms ADGRV1 as one of the three established USH2 genes.
- name: WHRN Mutations
  association: Causative
  subtype: USH2
  gene_term:
    preferred_term: WHRN
    term:
      id: hgnc:16361
      label: WHRN
  features: >
    Biallelic mutations in WHRN (whirlin) cause Usher syndrome type 2D. Whirlin
    is a PDZ scaffold protein that, with usherin and ADGRV1, organizes the
    ankle-link complex.
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Identification of biallelic pathogenic variants in one of three genes – ADGRV1, USH2A, or WHRN – establishes the diagnosis if clinical features are inconclusive."
    explanation: Confirms WHRN as one of the three established USH2 genes.
- name: CLRN1 Mutations
  association: Causative
  subtype: USH3
  gene_term:
    preferred_term: CLRN1
    term:
      id: hgnc:12605
      label: CLRN1
  features: >
    Biallelic mutations in CLRN1 (clarin-1) cause Usher syndrome type 3A.
    Clarin-1 is a four-transmembrane protein required for hair-bundle and
    photoreceptor synaptic/sensory function; CLRN1 founder mutations are
    prevalent in Finnish and Ashkenazi Jewish populations.
  evidence:
  - reference: PMID:11524702
    reference_title: "Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "USH3, the candidate gene that we \nidentified, encodes a 120-amino-acid protein."
    explanation: >-
      Identifies the USH3 causative gene (subsequently named CLRN1/clarin-1) whose
      mutations underlie Usher syndrome type 3.
  - reference: PMID:11524702
    reference_title: "Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Usher syndrome type 3 (USH3) is an autosomal recessive disorder characterized by \nprogressive hearing loss, severe retinal degeneration, and variably present \nvestibular dysfunction, assigned to 3q21-q25."
    explanation: >-
      Defines USH3 (the CLRN1/clarin-1 disorder at 3q21-q25) as autosomal-recessive
      hearing loss with retinal degeneration and variable vestibular dysfunction.
treatments:
- name: Vestibular Physical Therapy
  description: >
    Physical therapy / vestibular rehabilitation is recommended to manage the
    vestibular dysfunction and imbalance of USH1 (and to a lesser degree USH3)
    throughout the disease course, beginning in childhood.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  target_phenotypes:
  - preferred_term: Abnormal vestibular function
    term:
      id: HP:0001751
      label: Abnormal vestibular function
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical therapy is recommended to manage vestibular dysfunction \nand imbalance throughout the disease course"
    explanation: >-
      GeneReviews recommends physical therapy for the vestibular dysfunction and
      imbalance of USH1.
- name: Cochlear Implantation
  description: >
    Cochlear implantation provides auditory rehabilitation for the
    severe-to-profound sensorineural hearing loss of USH1 and is most effective
    when performed early in childhood, typically before age one year.
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: MAXO:0009025
      label: cochlear device implantation
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:20301442
    reference_title: "Usher Syndrome Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cochlear implantation should be considered as young as medically feasible, typically before age one year."
    explanation: GeneReviews recommends early cochlear implantation for the profound hearing loss of USH1.
- name: Hearing Aids
  description: >
    Conventional amplification with hearing aids is used for the moderate-to-
    severe hearing loss of USH2 and early USH3.
  treatment_term:
    preferred_term: hearing aid usage
    term:
      id: MAXO:0009030
      label: hearing aid usage
  target_phenotypes:
  - preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of manifestations: Early fitting of hearing aids and speech training."
    explanation: GeneReviews recommends early hearing-aid fitting for the hearing loss of USH2.
- name: Genetic Counseling
  description: >
    Genetic counseling addresses the autosomal recessive recurrence risk and
    informs reproductive decision-making and cascade testing.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301515
    reference_title: "Usher Syndrome Type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "USH2 is inherited in an autosomal recessive manner. Each subsequent pregnancy of a couple who have had a child with Usher syndrome type II has a 25% chance of resulting in an affected child"
    explanation: Supports genetic counseling for the autosomal recessive recurrence risk of Usher syndrome.
- name: Gene Therapy
  description: >
    Investigational gene-replacement, gene-editing, and antisense-oligonucleotide
    approaches target the retinal degeneration, including dual-AAV delivery for
    the large MYO7A and USH2A genes. No therapy is approved.
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  evidence:
  - reference: PMID:32995707
    reference_title: "Usher syndrome: clinical features, molecular genetics and advancing therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While there is currently no available approved treatment for the RP, various therapeutic strategies are in development or in clinical trials for Usher syndrome, including gene replacement, gene editing, antisense oligonucleotides and small molecule drugs."
    explanation: Documents the investigational gene-replacement/editing/ASO strategies targeting the retinal degeneration, none yet approved.

📚

References & Deep Research

References

2

PMID:20301442

Usher Syndrome Type I.

No top-level findings curated for this source.

PMID:20301515

Usher Syndrome Type II.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 23 citations 2026-06-22T10:34:17.874945

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Usher Syndrome
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Usher Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Due to token budget limitations, I must provide a summary report indicating that comprehensive data collection has been initiated. The full comprehensive report requested would require significantly more tool calls and analysis than can be completed within current constraints. Below is a partial preliminary report based on the evidence gathered thus far:

COMPREHENSIVE RESEARCH REPORT: USHER SYNDROME

1. DISEASE INFORMATION

Disease Overview

Usher syndrome (USH) is an autosomal recessive syndromic ciliopathy and represents the most common genetic cause of deaf-blindness worldwide (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2). The syndrome is clinically characterized by the combination of sensorineural hearing loss (SNHL), progressive vision loss due to rod-cone dystrophy or retinitis pigmentosa (RP), and variable vestibular dysfunction (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2, toms2020ushersyndromeclinical pages 1-2).

The disease was first described in 1858 by German ophthalmologist Albrecht von Graefe, but was named after Scottish ophthalmologist Charles Howard Usher, who in 1914 presented a comprehensive series of 69 affected patients from 40 families (castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2).

Key Identifiers

While specific MONDO IDs were not explicitly provided in the gathered literature, the following identifiers are documented:

OMIM IDs: - USH1B (MYO7A): #276900 / Gene #276903 - USH1C (USH1C): #276904 / Gene #605242
- USH1D (CDH23): #601067 / Gene #605516 - USH1F (PCDH15): #602083 / Gene #605514 - USH1G (USH1G/SANS): #606943 / Gene #607696 - USH2A (USH2A): #276901 / Gene #608400 - USH2C (ADGRV1): #605472 / Gene #602851 - USH2D (WHRN): #611383 / Gene #607928 - USH3A (CLRN1): #276902 / Gene #606397 (fustergarcia2021ushersyndromegenetics pages 1-2, toms2020ushersyndromeclinical pages 1-2, french2020areviewof pages 1-2)

Orphanet: The literature mentions Orphanet as a key resource but specific Orphanet ORPHA codes were not provided in the extracted text segments.

ICD Codes: Not explicitly mentioned in the gathered evidence, though the syndrome would fall under categories for hereditary retinal dystrophies and syndromic hearing loss.

Common Synonyms and Alternative Names

Usher's syndrome
Hallgren syndrome (historical, less commonly used)
Deaf-blindness, Usher type (castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2)

Data Source Classification

The information presented is derived from aggregated disease-level resources, including peer-reviewed publications, genetic databases (OMIM, ClinVar), disease registries (Target 5000 Irish IRD registry), and population-based studies, rather than individual patient-level EHR data (delmaghani2022thegeneticand pages 1-2, stephenson2023ushersyndromeon pages 1-2, karali2022geneticepidemiologyof pages 1-2).

2. ETIOLOGY

Disease Causal Factors

Genetic Causes:

Usher syndrome is primarily a monogenic, autosomal recessive disorder, though complex inheritance patterns including digenic forms have been reported (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2, whatley2020ushersyndromegenetics pages 1-2). To date, nine genes have been confirmed as causative when mutated: MYO7A, USH1C, CDH23, PCDH15, and USH1G (SANS) for Usher type 1; USH2A, ADGRV1, and WHRN for Usher type 2; and CLRN1 for Usher type 3 (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2).

A tenth gene, CIB2, was previously proposed but has been excluded by recent expert consensus (castiglione2022ushersyndrome pages 1-2, guimaraes2023inheritedcausesof pages 1-6).

The encoded proteins form a dynamic network called the "Usher interactome" that is essential for the development and maintenance of stereocilia in cochlear hair cells and for protein trafficking and structural integrity at the periciliary region of retinal photoreceptors (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2).

USH Type	Gene symbol	Protein name	Chromosome location (GRCh38)	Disease / subtype OMIM ID	Protein / gene function	Reported mutation frequency / prevalence contribution
USH1	MYO7A	Myosin VIIA	chr11:77128246–77215241	USH1B / 276900; gene 276903	Actin-based motor protein essential for hair-bundle structure/function and photoreceptor/periciliary transport	Major USH1 gene; reported to account for >50% of USH1 in one review; also listed as 21% of all genetically characterized USH cases in a large cohort summary (toms2020ushersyndromeclinical pages 1-2, french2020areviewof pages 1-2)
USH1	USH1C	Harmonin	chr11:17493895–17544416	USH1C / 276904; gene 605242	Scaffold protein in the Usher interactome; organizes protein complexes in stereocilia and photoreceptors	Rare cause; estimated ~2% of all USH cases in a cohort summary (french2020areviewof pages 1-2)
USH1	CDH23	Cadherin 23	chr10:71396934–71815947	USH1D / 601067; gene 605516	Cell-adhesion protein; component of stereociliary links important for mechanotransduction	Uncommon cause; estimated ~6% of all USH cases in a cohort summary (french2020areviewof pages 1-2)
USH1	PCDH15	Protocadherin 15	chr10:53802771–55627942	USH1F / 602083; gene 605514	Cell-adhesion / tip-link associated protein required for stereocilia cohesion and sensory transduction	Uncommon cause; estimated ~3% of all USH cases in a cohort summary (french2020areviewof pages 1-2)
USH1	USH1G	SANS	chr17:73223675–73258264	USH1G / 606943; gene 607696	Scaffold/adaptor protein within the Usher protein network in hair cells and photoreceptors	Very rare; estimated ~1% of all USH cases in a cohort summary (french2020areviewof pages 1-2)
USH2	USH2A	Usherin	chr1:215622891–216423448	USH2A / 276901; gene 608400	Extracellular matrix / transmembrane-associated Usher complex component at photoreceptor periciliary membrane and base of hair bundles	Principal USH2 gene; reported to cause ~80% of USH2 in one review, 50% of all USH cases in another cohort summary, and 50% of all USH2 cases in a focused USH2 review (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3, french2020areviewof pages 1-2)
USH2	ADGRV1	Adhesion G protein-coupled receptor V1 (VLGR1)	chr5:89942634–90549316	USH2C / 605472; gene 602851	Very large adhesion GPCR; part of the USH2 complex in hair bundles and photoreceptor periciliary region	Less common USH2 cause; estimated ~5% of all USH cases in a cohort summary (french2020areviewof pages 1-2)
USH2	WHRN	Whirlin	chr9:117382790–117481605	USH2D / 611383; gene 607928	PDZ-domain scaffold protein in the USH2 complex; supports stereocilia elongation/organization and photoreceptor protein networks	Rare USH2 cause; estimated ~0.4% of all USH cases in a cohort summary (french2020areviewof pages 1-2)
USH3	CLRN1	Clarin-1	chr3:150928506–150975693	USH3A / 276902; gene 606397	Four-transmembrane protein implicated in hair-cell and photoreceptor synaptic/sensory function	Main confirmed USH3 gene; estimated ~2% of all USH cases overall, but markedly enriched in Finnish and Ashkenazi Jewish populations where >40% of USH can be USH3 (subtype prevalence, not gene share) (guimaraes2023inheritedcausesof pages 1-6, french2020areviewof pages 1-2)
Contested / no longer generally accepted as confirmed	CIB2	Calcium and integrin-binding family member 2	—	Formerly proposed USH1J / gene 605564	Initially proposed Usher-related protein; later reviews note it is no longer generally considered a confirmed Usher gene	Included in some older 10-gene lists, but multiple reviews caution against counting it among confirmed causative genes (castiglione2022ushersyndrome pages 1-2, guimaraes2023inheritedcausesof pages 1-6)

Table: This table summarizes the confirmed major Usher syndrome genes by clinical subtype, with protein names, genomic locations, OMIM identifiers, core functions, and reported contribution to disease burden. It is useful for quickly comparing the relative importance and biological roles of USH1, USH2, and USH3 genes.

Mechanistic Basis:

In the inner ear, Usher proteins are critical for the correct development and maintenance of the structure and cohesion of stereocilia—the mechanosensitive organelles on auditory and vestibular hair cells. Disease-causing mutations destabilize the tip links that bind stereocilia together and cause defects in protein trafficking and stereocilia bundle morphology, thereby inhibiting mechanotransduction of sound waves into electrical signals (fustergarcia2021ushersyndromegenetics pages 1-2, whatley2020ushersyndromegenetics pages 1-2).

In the retina, the Usher protein network localizes principally to the periciliary region of photoreceptors and plays an important role in maintaining periciliary structure and trafficking molecules between the inner and outer segments of photoreceptors. Disruption of these processes leads to progressive photoreceptor degeneration characteristic of retinitis pigmentosa (fustergarcia2021ushersyndromegenetics pages 1-2, delmaghani2022thegeneticand pages 1-2).

Risk Factors

Genetic Risk Factors:

Autosomal recessive inheritance: Both parents must be carriers (heterozygous) for a child to be affected (homozygous or compound heterozygous). Carrier frequency is elevated in populations with consanguinity or founder effects (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2).
Founder effects: Certain populations show enrichment of specific USH mutations. For example, USH3 (CLRN1 mutations) is particularly prevalent in Finnish and Ashkenazi Jewish populations, where it accounts for >40% of USH cases, compared to 1-6% in other populations (guimaraes2023inheritedcausesof pages 1-6, french2020areviewof pages 1-2).
Modifier genes: PDZD7 has been identified as a modifier gene that can aggravate the phenotype when present with mutations in USH2 genes (USH2A, ADGRV1, WHRN), though it is not independently causative (castiglione2022ushersyndrome pages 1-2, french2020areviewof pages 1-2).
Digenic inheritance: Rare cases of digenic inheritance involving mutations in two different USH genes or a USH gene plus PDZD7 have been reported in mice and humans (whatley2020ushersyndromegenetics pages 1-2).

Environmental Risk Factors:

Limited evidence exists for environmental risk factors in Usher syndrome as it is primarily a genetic disorder. However:

Light exposure has been shown in animal models to exacerbate photoreceptor degeneration, suggesting that bright light may accelerate vision loss (fustergarcia2021ushersyndromegenetics pages 1-2).
Consanguinity increases risk of autosomal recessive conditions including USH in offspring (fustergarcia2021ushersyndromegenetics pages 1-2).

Protective Factors

Genetic Protective Factors:

No clearly defined protective genetic variants have been identified in the gathered literature. However:

Heterozygous carriers of single USH mutations are generally asymptomatic, though recent studies suggest some USH2A heterozygous carriers may experience unexpected low-frequency hearing loss and reduced early vocabulary, challenging the traditional assumption that carriers are entirely unaffected (stemerdink2022geneticspathogenesisand pages 1-3).

Environmental Protective Factors:

No specific environmental protective factors have been definitively established. Potential areas for consideration include:

Early auditory intervention (hearing aids, cochlear implants) and visual aids may slow functional decline and improve quality of life, though they do not alter the underlying pathophysiology (castiglione2022ushersyndrome pages 1-2, toms2020ushersyndromeclinical pages 1-2, french2020areviewof pages 1-2).
Avoidance of excessive light exposure may theoretically reduce photostress and slow retinal degeneration, based on animal model data, though clinical evidence is lacking (fustergarcia2021ushersyndromegenetics pages 1-2).

Gene-Environment Interactions

Direct gene-environment interaction studies are scarce in the USH literature reviewed. The primary gene-environment consideration relates to:

Light exposure and genetic background: The rate of photoreceptor degeneration may be modulated by environmental light exposure in conjunction with the specific genetic defect, as suggested by preclinical models showing light-induced photostress reduction of mitochondrial function (fustergarcia2021ushersyndromegenetics pages 1-2).

3. PHENOTYPES

Usher syndrome is traditionally classified into three clinical subtypes (USH1, USH2, USH3) based on the severity and onset of hearing loss, presence or absence of vestibular dysfunction, and age at onset of retinitis pigmentosa (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2, toms2020ushersyndromeclinical pages 1-2).

Usher subtype	Sensorineural hearing loss (onset / severity / progression)	Retinitis pigmentosa / visual features	Vestibular function	Age of onset summary	Key distinguishing features	Suggested HPO terms
USH1	Congenital, severe-to-profound, usually prelingual SNHL; often described as non-progressive or minimally progressive in classic presentations (toms2020ushersyndromeclinical pages 1-2, delmaghani2022thegeneticand pages 2-4)	Prepubertal / first-decade onset rod-cone dystrophy or RP; progressive night blindness, peripheral visual field constriction, later severe visual impairment/legal blindness often by the fourth decade in classic descriptions (toms2020ushersyndromeclinical pages 1-2, delmaghani2022thegeneticand pages 2-4)	Vestibular areflexia / marked hypofunction is typical; delayed motor milestones, many children walking after 18 months (toms2020ushersyndromeclinical pages 1-2, delmaghani2022thegeneticand pages 2-4)	Hearing: birth; Vision: first decade / prepubertal; Balance: infancy (toms2020ushersyndromeclinical pages 1-2, delmaghani2022thegeneticand pages 2-4)	Most severe classic form; congenital deafness plus early RP and absent vestibular function; speech may not develop without early auditory intervention such as cochlear implantation (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6)	HP:0000407 Sensorineural hearing impairment; HP:0000369 Progressive deafness; HP:0000510 Visual impairment; HP:0000556 Retinal dystrophy; HP:0000662 Night blindness; HP:0001123 Constriction of visual field; HP:0001756 Vestibular dysfunction; HP:0002194 Delayed gross motor development
USH2	Congenital/early-onset, moderate-to-severe, classically down-sloping high-frequency SNHL; speech generally intelligible; once considered stable, but multiple studies report progression, especially at high frequencies (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3, delmaghani2022thegeneticand pages 2-4)	Second-decade onset RP; progressive nyctalopia and concentric visual field loss; average diagnosis often in the third decade; cataract and cystoid macular edema are relatively common in USH cohorts (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6, stephenson2023ushersyndromeon pages 1-2)	Usually normal vestibular function, though some series report variable or subtle dysfunction in a subset (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3, delmaghani2022thegeneticand pages 2-4)	Hearing: birth/early childhood; Vision: second decade; Balance: usually normal (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3)	Most common subtype; milder auditory phenotype than USH1, later retinal disease, and absent/less prominent vestibular signs; often associated with USH2A (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3, french2020areviewof pages 1-2)	HP:0000407 Sensorineural hearing impairment; HP:0001329 High-frequency sensorineural hearing impairment; HP:0000510 Visual impairment; HP:0000556 Retinal dystrophy; HP:0000662 Night blindness; HP:0001123 Constriction of visual field; HP:0000545 Myopia; HP:0000518 Cataract
USH3	Postlingual, progressive, variable SNHL; hearing may be normal or near-normal in early life, then worsens over time to severe/profound deafness in many affected individuals (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6, delmaghani2022thegeneticand pages 2-4)	Variable onset, often postpubertal or in the second decade, with progressive RP causing nyctalopia and visual field constriction (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6)	Variable vestibular dysfunction, present in about half of affected individuals in some summaries (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6)	Hearing: childhood to adolescence, postlingual; Vision: variable, often second decade or later; Balance: variable onset (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6)	Rarest classic subtype in many Western populations; characterized chiefly by progressive rather than congenital-fixed auditory loss and marked intrafamilial/interindividual variability (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6, delmaghani2022thegeneticand pages 2-4)	HP:0000407 Sensorineural hearing impairment; HP:0000369 Progressive deafness; HP:0000510 Visual impairment; HP:0000556 Retinal dystrophy; HP:0000662 Night blindness; HP:0001123 Constriction of visual field; HP:0001756 Vestibular dysfunction

Table: This table summarizes the defining clinical phenotypes of USH1, USH2, and USH3, including hearing, retinal, and vestibular features, timing of onset, and distinguishing traits. It also provides suggested HPO terms to support phenotype annotation in a disease knowledge base.

USH1 Phenotypes

Hearing Loss: - Type: Sensorineural hearing loss (SNHL) - Onset: Congenital, present at birth (prelingual) - Severity: Severe to profound - Progression: Classically described as non-progressive or minimally progressive - Frequency: Present in 100% of USH1 patients - Impact on QOL: Profound; without early intervention (hearing aids, cochlear implants), speech development is severely impaired - HPO terms: HP:0000407 (Sensorineural hearing impairment), HP:0008527 (Congenital sensorineural hearing impairment), HP:0000369 (Progressive deafness - for rare progressive cases) (toms2020ushersyndromeclinical pages 1-2, delmaghani2022thegeneticand pages 2-4)

Retinitis Pigmentosa: - Type: Rod-cone dystrophy - Onset: Prepubertal, typically within the first decade of life - Progression: Progressive; legal blindness often by the fourth decade - Severity: Severe - Frequency: Present in 100% of USH1 patients - Key findings: Night blindness (nyctalopia), peripheral visual field constriction (tunnel vision), bone-spicule pigmentation on fundoscopy - HPO terms: HP:0000510 (Visual impairment), HP:0000556 (Retinal dystrophy), HP:0000662 (Night blindness), HP:0001123 (Constriction of visual field), HP:0000580 (Pigmentary retinopathy) (toms2020ushersyndromeclinical pages 1-2, delmaghani2022thegeneticand pages 2-4)

Vestibular Dysfunction: - Type: Bilateral vestibular areflexia - Onset: Congenital/infancy - Severity: Severe, absent vestibular responses - Frequency: Present in most/all USH1 patients - Key findings: Delayed motor milestones, most children do not walk before 18 months of age - HPO terms: HP:0001756 (Vestibular dysfunction), HP:0002194 (Delayed gross motor development), HP:0002510 (Areflexia of the lower limbs - vestibular context) (toms2020ushersyndromeclinical pages 1-2, delmaghani2022thegeneticand pages 2-4)

USH2 Phenotypes

Hearing Loss: - Type: Sensorineural hearing loss - Onset: Congenital or early childhood - Severity: Moderate to severe, typically with a down-sloping audiogram (higher frequencies more affected) - Progression: Previously considered stable, but recent studies document progressive hearing loss, especially at high frequencies - Frequency: Present in 100% of USH2 patients - Speech: Generally intelligible - Impact on QOL: Moderate to severe; speech is usually preserved with hearing aids - HPO terms: HP:0000407 (Sensorineural hearing impairment), HP:0001329 (High-frequency sensorineural hearing impairment) (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3, delmaghani2022thegeneticand pages 2-4)

Retinitis Pigmentosa: - Onset: Second decade of life - Progression: Progressive; average age of diagnosis in third decade; cataract and cystoid macular edema are relatively common (present in >50% in some cohorts) - Frequency: Present in 100% of USH2 patients - Key findings: Night blindness, concentric visual field loss, myopia is common, cataracts - HPO terms: HP:0000556 (Retinal dystrophy), HP:0000662 (Night blindness), HP:0001123 (Constriction of visual field), HP:0000545 (Myopia), HP:0000518 (Cataract), HP:0007754 (Cystoid macular edema) (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6, stephenson2023ushersyndromeon pages 1-2)

Vestibular Function: - Typically normal, though some studies report variable or subtle vestibular dysfunction in a subset of patients - HPO term: HP:0002403 (Normal vestibular function - for majority), HP:0001756 (Vestibular dysfunction - for variant presentations) (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3, delmaghani2022thegeneticand pages 2-4)

USH3 Phenotypes

Hearing Loss: - Type: Sensorineural hearing loss - Onset: Postlingual, variable (childhood to adolescence) - Severity: Progressive, ranging from mild to profound over time - Progression: Progressive; many individuals develop severe to profound deafness - Frequency: Present in 100% of USH3 patients - Speech: Normal early development, but may deteriorate with progressive hearing loss - HPO terms: HP:0000407 (Sensorineural hearing impairment), HP:0000369 (Progressive deafness) (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6, delmaghani2022thegeneticand pages 2-4)

Retinitis Pigmentosa: - Onset: Variable, often postpubertal or in the second decade - Progression: Progressive - Frequency: Present in 100% of USH3 patients - HPO terms: HP:0000556 (Retinal dystrophy), HP:0000662 (Night blindness), HP:0001123 (Constriction of visual field) (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6)

Vestibular Function: - Variable; vestibular dysfunction present in approximately 50% of affected individuals - HPO term: HP:0001756 (Vestibular dysfunction) (toms2020ushersyndromeclinical pages 1-2, guimaraes2023inheritedcausesof pages 1-6)

Additional Phenotypic Features

Emerging evidence suggests additional comorbidities beyond the classic triad:

Sleep disturbances have been associated with USH2, though the molecular basis remains unclear (stemerdink2022geneticspathogenesisand pages 1-3)
Olfactory dysfunction and tactile perception deficits have been reported in some USH2 patients (stemerdink2022geneticspathogenesisand pages 1-3)
Reduced sperm motility has been observed, consistent with the ciliopathy nature of the disease (stemerdink2022geneticspathogenesisand pages 1-3)

4. GENETIC/MOLECULAR INFORMATION

Causal Genes

Nine genes are confirmed as causative of Usher syndrome when mutated (fustergarcia2021ushersyndromegenetics pages 1-2, castiglione2022ushersyndrome pages 1-2, delmaghani2022thegeneticand pages 1-2):

USH1 Genes: - MYO7A (OMIM 276903): Encodes myosin VIIA, an actin-based motor protein - USH1C (OMIM 605242): Encodes harmonin, a scaffold protein - CDH23 (OMIM 605516): Encodes cadherin 23, a cell-adhesion protein - PCDH15 (OMIM 605514): Encodes protocadherin 15, a cell-adhesion protein - USH1G (OMIM *607696): Encodes SANS, a scaffold protein

USH2 Genes: - USH2A (OMIM 608400): Encodes usherin, an extracellular matrix protein - ADGRV1 (OMIM 602851): Encodes adhesion GPCR V1 (VLGR1) - WHRN (OMIM *607928): Encodes whirlin, a PDZ-domain scaffold protein

USH3 Gene: - CLRN1 (OMIM *606397): Encodes clarin-1, a four-transmembrane protein

(See artifact-00 for comprehensive gene table)

Pathogenic Variants

Major genes and mutation frequencies:

MYO7A: Accounts for >50% of USH1 cases and ~21% of all genetically characterized USH cases. Both missense and truncating mutations have been identified (toms2020ushersyndromeclinical pages 1-2, french2020areviewof pages 1-2).
USH2A: The most frequently mutated USH gene overall, responsible for approximately 80% of USH2 cases and ~50% of all USH cases in some cohorts. It is also the most common cause of autosomal recessive non-syndromic RP (toms2020ushersyndromeclinical pages 1-2, stemerdink2022geneticspathogenesisand pages 1-3, french2020areviewof pages 1-2, karali2022geneticepidemiologyof pages 1-2). The variant c.2299delG in USH2A is particularly prevalent, with frequencies as high as 77.5% in some USH2 cohorts, likely representing an ancestral mutation (guimaraes2023inheritedcausesof pages 1-6).
ADGRV1: Accounts for ~5% of all USH cases (french2020areviewof pages 1-2).
CDH23: Accounts for ~6% of all USH cases (french2020areviewof pages 1-2).
Other genes (USH1C, PCDH15, USH1G, WHRN, CLRN1) individually account for ≤3% of all USH cases, with some genes being very rare except in specific populations (e.g., CLRN1 in Finnish and Ashkenazi Jewish populations) (guimaraes2023inheritedcausesof pages 1-6, french2020areviewof pages 1-2).

Variant classification:

Variants are classified according to ACMG/AMP guidelines as pathogenic, likely pathogenic, or variants of uncertain significance (VUS). In one large Italian IRD cohort, ABCA4 was the most frequently mutated gene (26.3% of solved cases), followed by USH2A (11.2%, n=228 patients), indicating the high contribution of USH2A to the overall IRD burden (karali2022geneticepidemiologyof pages 1-2).

Variant types:

Pathogenic variants in USH genes include: - Missense mutations (single amino acid substitutions) - Nonsense mutations (premature stop codons) - Frameshift mutations (insertions/deletions causing reading frame shifts) - Splice-site mutations (affecting mRNA splicing) - Large deletions/duplications (structural variants)

Almost half of identified variants in recent cohorts are novel, highlighting ongoing genetic heterogeneity (fustergarcia2021ushersyndromegenetics pages 1-2).

Allele frequencies:

Population-specific allele frequencies vary. The c.2299delG variant in USH2A is notably common in USH2 patients but rare in the general population. A comparison of disease prevalence to genetic prevalence calculated from gnomAD allele frequencies showed general correlation but some discordance, suggesting that certain presumed pathogenic variants may be nonpathogenic or hypomorphic (hanany2024comparisonofworldwide pages 1-2).

Somatic vs. germline:

Usher syndrome is a germline disorder; all causative variants are inherited or arise de novo in the germline, not somatically acquired.

Functional consequences:

Loss of function is the predominant mechanism for most USH genes, resulting in absent or non-functional protein products.
Dominant-negative effects have been proposed for some missense variants, particularly in genes encoding multimeric structural proteins.
Hypomorphic alleles with residual function may result in milder or atypical phenotypes.

Modifier Genes

PDZD7 is a recognized modifier gene that can exacerbate the USH2 phenotype when mutated in combination with USH2A, ADGRV1, or WHRN mutations, but is not independently causative (castiglione2022ushersyndrome pages 1-2, french2020areviewof pages 1-2).

Epigenetic Information

No specific epigenetic modifications (DNA methylation, histone modifications) were detailed in the gathered USH literature, though this remains an area for further investigation.

Chromosomal Abnormalities

Usher syndrome is not typically associated with large-scale chromosomal abnormalities (aneuploidies, translocations, inversions). It is caused by sequence-level mutations in specific genes.

5. ENVIRONMENTAL INFORMATION

Usher syndrome is overwhelmingly a genetic disorder with minimal documented environmental contributions to disease causation. However, environmental factors may modulate disease progression:

Light exposure: Preclinical models suggest bright light exacerbates photoreceptor degeneration (fustergarcia2021ushersyndromegenetics pages 1-2).
Consanguinity: While not an environmental factor per se, consanguineous unions increase the likelihood of autosomal recessive conditions in offspring (fustergarcia2021ushersyndromegenetics pages 1-2).

No specific infectious agents, toxins, radiation, pollution, or occupational exposures have been implicated in USH etiology.

LIMITATIONS AND NOTE

This report represents a preliminary summary based on initial literature retrieval. The comprehensive, full-scale report requested covering all 15 sections (Disease Information, Etiology, Phenotypes, Genetic/Molecular Information, Environmental Information, Mechanism/Pathophysiology, Anatomical Structures, Temporal Development, Inheritance and Population, Diagnostics, Outcome/Prognosis, Treatment, Prevention, Other Species/Natural Disease, and Model Organisms) with complete citations, ontology terms, direct quotes from abstracts, and detailed tables would require substantial additional tool calls, evidence gathering, artifact creation, and synthesis that exceed current token and time constraints.

For a full comprehensive report suitable for populating a disease knowledge base, additional work is needed to: - Gather detailed mechanistic and pathophysiology information with GO terms - Identify anatomical structures with UBERON and Cell Ontology terms - Research temporal development, disease stages, and natural history - Collect inheritance patterns, penetrance, expressivity, and epidemiology data with specific prevalence/incidence figures - Detail diagnostic approaches including genetic testing strategies, biomarkers, and clinical criteria - Compile outcome and prognosis information including survival rates, quality of life measures - Summarize treatment modalities with MAXO terms, including ongoing clinical trials - Document prevention strategies and genetic counseling approaches - Review model organisms (mouse, zebrafish, Drosophila) with phenotype recapitulation details - Create additional comprehensive tables for variants, treatments, diagnostics, and model organisms

This preliminary report should serve as a foundation, with the understanding that comprehensive knowledge base population will require continued systematic evidence gathering and synthesis.

References

(fustergarcia2021ushersyndromegenetics pages 1-2): Carla Fuster-García, Belén García-Bohórquez, Ana Rodríguez-Muñoz, Elena Aller, Teresa Jaijo, José M. Millán, and Gema García-García. Usher syndrome: genetics of a human ciliopathy. International Journal of Molecular Sciences, 22:6723, Jun 2021. URL: https://doi.org/10.3390/ijms22136723, doi:10.3390/ijms22136723. This article has 135 citations.
(castiglione2022ushersyndrome pages 1-2): Alessandro Castiglione and Claes Möller. Usher syndrome. Audiology Research, 12:42-65, Jan 2022. URL: https://doi.org/10.3390/audiolres12010005, doi:10.3390/audiolres12010005. This article has 114 citations.
(delmaghani2022thegeneticand pages 1-2): Sedigheh Delmaghani and Aziz El-Amraoui. The genetic and phenotypic landscapes of usher syndrome: from disease mechanisms to a new classification. Human Genetics, 141:709-735, Mar 2022. URL: https://doi.org/10.1007/s00439-022-02448-7, doi:10.1007/s00439-022-02448-7. This article has 160 citations and is from a peer-reviewed journal.
(toms2020ushersyndromeclinical pages 1-2): Maria Toms, Waheeda Pagarkar, and Mariya Moosajee. Usher syndrome: clinical features, molecular genetics and advancing therapeutics. Therapeutic Advances in Ophthalmology, Jan 2020. URL: https://doi.org/10.1177/2515841420952194, doi:10.1177/2515841420952194. This article has 142 citations and is from a peer-reviewed journal.
(french2020areviewof pages 1-2): Lucy S. French, Carla B. Mellough, Fred K. Chen, and Livia S. Carvalho. A review of gene, drug and cell-based therapies for usher syndrome. Frontiers in Cellular Neuroscience, Jul 2020. URL: https://doi.org/10.3389/fncel.2020.00183, doi:10.3389/fncel.2020.00183. This article has 39 citations.
(stephenson2023ushersyndromeon pages 1-2): Kirk A. J. Stephenson, Laura Whelan, Julia Zhu, Adrian Dockery, Niamh C. Wynne, Rebecca M. Cairns, Claire Kirk, Jacqueline Turner, Emma S. Duignan, James J. O'Byrne, Giuliana Silvestri, Paul F. Kenna, G. Jane Farrar, and David J. Keegan. Usher syndrome on the island of ireland: a genotype-phenotype review. Investigative Opthalmology & Visual Science, 64:23, Jul 2023. URL: https://doi.org/10.1167/iovs.64.10.23, doi:10.1167/iovs.64.10.23. This article has 13 citations.
(karali2022geneticepidemiologyof pages 1-2): Marianthi Karali, Francesco Testa, Valentina Di Iorio, Annalaura Torella, Roberta Zeuli, Margherita Scarpato, Francesca Romano, Maria Elena Onore, Mariateresa Pizzo, Paolo Melillo, Raffaella Brunetti-Pierri, Ilaria Passerini, Elisabetta Pelo, Frans P. M. Cremers, Gabriella Esposito, Vincenzo Nigro, Francesca Simonelli, and Sandro Banfi. Genetic epidemiology of inherited retinal diseases in a large patient cohort followed at a single center in italy. Scientific Reports, Dec 2022. URL: https://doi.org/10.1038/s41598-022-24636-1, doi:10.1038/s41598-022-24636-1. This article has 95 citations and is from a peer-reviewed journal.
(whatley2020ushersyndromegenetics pages 1-2): Meg Whatley, Abbie Francis, Zi Ying Ng, Xin Ee Khoh, Marcus D. Atlas, Rodney J. Dilley, and Elaine Y. M. Wong. Usher syndrome: genetics and molecular links of hearing loss and directions for therapy. Frontiers in Genetics, Oct 2020. URL: https://doi.org/10.3389/fgene.2020.565216, doi:10.3389/fgene.2020.565216. This article has 65 citations and is from a peer-reviewed journal.
(guimaraes2023inheritedcausesof pages 1-6): Thales Antonio Cabral de Guimaraes, Elizabeth Arram, Ahmed F Shakarchi, Michalis Georgiou, and Michel Michaelides. Inherited causes of combined vision and hearing loss: clinical features and molecular genetics. British Journal of Ophthalmology, 107:1403-1414, Sep 2023. URL: https://doi.org/10.1136/bjo-2022-321790, doi:10.1136/bjo-2022-321790. This article has 30 citations and is from a highest quality peer-reviewed journal.
(stemerdink2022geneticspathogenesisand pages 1-3): M. Stemerdink, B. García-Bohórquez, R. Schellens, G. Garcia-Garcia, E. Van Wijk, and J. M. Millan. Genetics, pathogenesis and therapeutic developments for usher syndrome type 2. Human Genetics, 141:737-758, Jul 2022. URL: https://doi.org/10.1007/s00439-021-02324-w, doi:10.1007/s00439-021-02324-w. This article has 45 citations and is from a peer-reviewed journal.
(delmaghani2022thegeneticand pages 2-4): Sedigheh Delmaghani and Aziz El-Amraoui. The genetic and phenotypic landscapes of usher syndrome: from disease mechanisms to a new classification. Human Genetics, 141:709-735, Mar 2022. URL: https://doi.org/10.1007/s00439-022-02448-7, doi:10.1007/s00439-022-02448-7. This article has 160 citations and is from a peer-reviewed journal.
(hanany2024comparisonofworldwide pages 1-2): Mor Hanany, Sapir Shalom, Tamar Ben-Yosef, and Dror Sharon. Comparison of worldwide disease prevalence and genetic prevalence of inherited retinal diseases and variant interpretation considerations. Cold Spring Harbor perspectives in medicine, 14:a041277, Jul 2024. URL: https://doi.org/10.1101/cshperspect.a041277, doi:10.1101/cshperspect.a041277. This article has 45 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

COMPREHENSIVE RESEARCH REPORT: USHER SYNDROME

1. DISEASE INFORMATION

Disease Overview

Key Identifiers

Common Synonyms and Alternative Names

Data Source Classification

2. ETIOLOGY

Disease Causal Factors

Risk Factors

Protective Factors

Gene-Environment Interactions

3. PHENOTYPES

USH1 Phenotypes

USH2 Phenotypes

USH3 Phenotypes

Additional Phenotypic Features

4. GENETIC/MOLECULAR INFORMATION

Causal Genes

Pathogenic Variants

Modifier Genes

Epigenetic Information

Chromosomal Abnormalities

5. ENVIRONMENTAL INFORMATION

LIMITATIONS AND NOTE

Artifacts